drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00604 | DB00934 | 1,425 | 413 | [
"DDInter385",
"DDInter1124"
] | Cisapride | Maprotiline | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression. | Major | 2 | [
[
[
1425,
25,
413
]
],
[
[
1425,
64,
1302
],
[
1302,
40,
413
]
],
[
[
1425,
64,
847
],
[
847,
1,
413
]
],
[
[
1425,
6,
5744
],
[
5744,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Maprotiline"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
"... | Cisapride may lead to a major life threatening interaction when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Cisapride may lead to a major life threatening interaction when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotiline (Compound)
Cisapride (Compound) binds HTR2C (Gene) and HTR2C (Gene) is bound by Maprotiline (Compound)
Cisapride (Compound) downregulates NT5DC2 (Gene) and NT5DC2 (Gene) is downregulated by Maprotiline (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Maprotiline
Cisapride may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Cisapride may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Cisapride may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline |
DB00553 | DB08912 | 92 | 1,040 | [
"DDInter1177",
"DDInter462"
] | Methoxsalen | Dabrafenib | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
92,
24,
1040
]
],
[
[
92,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
92,
7,
13128
],
[
13128,
46,
1040
]
],
[
[
92,
18,
20113
],
[
20113,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Methoxsalen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Methoxsalen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Methoxsalen (Compound) upregulates NARFL (Gene) and NARFL (Gene) is upregulated by Dabrafenib (Compound)
Methoxsalen (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Dabrafenib (Compound)
Methoxsalen (Compound) upregulates PXN (Gene) and PXN (Gene) is downregulated by Dabrafenib (Compound)
Methoxsalen (Compound) causes Dermatitis acneiform (Side Effect) and Dermatitis acneiform (Side Effect) is caused by Dabrafenib (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib |
DB00563 | DB11732 | 663 | 1,097 | [
"DDInter1174",
"DDInter1027"
] | Methotrexate | Lasmiditan | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less suitable for use in patients with pre-existing cardiovascular disorders. Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically implicated in their vasoconstrictive activity.[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for the adverse effect profile of its predecessors - in other words, lasmiditan’s selectivity allows for the successful termination of migraines without causing vasoconstriction.[A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class of anti-migraine medications in which lasmiditan is the first and only member: the neurally-acting anti-migraine medications (NAAMAs).[A187322,A187307] | Moderate | 1 | [
[
[
663,
24,
1097
]
],
[
[
663,
24,
971
],
[
971,
63,
1097
]
],
[
[
663,
24,
77
],
[
77,
24,
1097
]
],
[
[
663,
64,
1064
],
[
1064,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methotrexate may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methotrexate may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Lasmiditan
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Methotrexate may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan |
DB00087 | DB00853 | 599 | 1,686 | [
"DDInter41",
"DDInter1762"
] | Alemtuzumab | Temozolomide | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual apoptosis.[A229853, A229923] Temozomolide as an adjunct to radiotherapy followed by maintenance dosing remains the standard of care for both Glioblastoma and refractory anaplastic astrocytoma. Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. It is currently marketed under the trademark TEMODAR® by Merck. | Moderate | 1 | [
[
[
599,
24,
1686
]
],
[
[
599,
24,
970
],
[
970,
24,
1686
]
],
[
[
599,
24,
1330
],
[
1330,
63,
1686
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Alemtuzumab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Temozolomide
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Temozolomide
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Temozolomide
Alemtuzumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Temozolomide
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil (Compound) treats skin cancer (Disease) and skin cancer (Disease) is treated by Temozolomide (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temozolomide (Compound) |
DB08867 | DB11730 | 807 | 351 | [
"DDInter1897",
"DDInter1588"
] | Ulipristal | Ribociclib | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity. Ulipristal is currently recommended as first line therapy for emergency contraception, due to improved efficacy and similar side effect profile as compared to the traditional use of levonorgestrel or the Yuzpe regimen. The exact mechanism of action for ulipristal is still currently debated, though there is evidence that it functions by inhibiting ovulation. A recent systematic review proclaimed that the majority of available evidence demonstrates | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
807,
24,
351
]
],
[
[
807,
63,
1409
],
[
1409,
24,
351
]
],
[
[
807,
24,
98
],
[
98,
24,
351
]
],
[
[
807,
24,
710
],
[
710,
63,... | [
[
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
... | Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Ribociclib
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Ribociclib
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ribociclib
Ulipristal may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Ribociclib
Ulipristal may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may lead to a major life threatening interaction when taken with Ribociclib |
DB00317 | DB01045 | 883 | 463 | [
"DDInter810",
"DDInter1590"
] | Gefitinib | Rifampicin | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Moderate | 1 | [
[
[
883,
24,
463
]
],
[
[
883,
24,
690
],
[
690,
40,
463
]
],
[
[
883,
6,
10215
],
[
10215,
45,
463
]
],
[
[
883,
63,
1101
],
[
1101,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Gefitinib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rifampicin (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Gefitinib (Compound) resembles Vandetanib (Compound) and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Gefitinib (Compound) resembles Erlotinib (Compound) and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Gefitinib (Compound) resembles Lapatinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin |
DB09049 | DB11978 | 1,135 | 124 | [
"DDInter1261",
"DDInter822"
] | Naloxegol | Glasdegib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Minor | 0 | [
[
[
1135,
23,
124
]
],
[
[
1135,
62,
79
],
[
79,
24,
124
]
],
[
[
1135,
25,
1339
],
[
1339,
63,
124
]
],
[
[
1135,
24,
98
],
[
98,
2... | [
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sorafenib"
],
[
"Sor... | Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may lead to a major life threatening interaction when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib |
DB00026 | DB06595 | 1,184 | 1,491 | [
"DDInter94",
"DDInter1214"
] | Anakinra | Midostaurin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Moderate | 1 | [
[
[
1184,
24,
1491
]
],
[
[
1184,
24,
58
],
[
58,
24,
1491
]
],
[
[
1184,
24,
270
],
[
270,
63,
1491
]
],
[
[
1184,
25,
1377
],
[
1377,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anakinra may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Midostaurin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Midostaurin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Midostaurin
Anakinra may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Midostaurin
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Midostaurin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin |
DB06616 | DB06717 | 594 | 875 | [
"DDInter224",
"DDInter778"
] | Bosutinib | Fosaprepitant | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Major | 2 | [
[
[
594,
25,
875
]
],
[
[
594,
64,
723
],
[
723,
1,
875
]
],
[
[
594,
21,
29122
],
[
29122,
60,
875
]
],
[
[
594,
63,
1101
],
[
1101,
... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} ... | Bosutinib may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Bosutinib (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Fosaprepitant (Compound)
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Bosutinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Bosutinib (Compound) resembles Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Bosutinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Fosaprepitant |
DB00443 | DB01324 | 251 | 178 | [
"DDInter195",
"DDInter1490"
] | Betamethasone | Polythiazide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
251,
24,
178
]
],
[
[
251,
24,
674
],
[
674,
40,
178
]
],
[
[
251,
63,
323
],
[
323,
40,
178
]
],
[
[
251,
21,
28835
],
[
28835,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles Polythiazide (Compound)
Betamethasone (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Polythiazide (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide |
DB00106 | DB01255 | 618 | 633 | [
"DDInter4",
"DDInter1078"
] | Abarelix | Lisdexamfetamine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space. | Moderate | 1 | [
[
[
618,
24,
633
]
],
[
[
618,
23,
112
],
[
112,
23,
633
]
],
[
[
618,
24,
1494
],
[
1494,
24,
633
]
],
[
[
618,
24,
286
],
[
286,
6... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lisdexamfetamine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine
Abarelix may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Lisdexamfetamine
Abarelix may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Lisdexamfetamine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Lisdexamfetamine
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) causes Psychotic disorder (Side Effect) and Psychotic disorder (Side Effect) is caused by Lisdexamfetamine (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Lisinopril and Lisinopril (Compound) resembles Lisdexamfetamine (Compound) |
DB09061 | DB11363 | 1,627 | 1,276 | [
"DDInter284",
"DDInter39"
] | Cannabidiol | Alectinib | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance. | Moderate | 1 | [
[
[
1627,
24,
1276
]
],
[
[
1627,
63,
305
],
[
305,
24,
1276
]
],
[
[
1627,
24,
1613
],
[
1613,
24,
1276
]
],
[
[
1627,
62,
384
],
[
384,
... | [
[
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia c... | Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Cannabidiol may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Alectinib
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib |
DB00563 | DB01028 | 663 | 1,332 | [
"DDInter1174",
"DDInter1179"
] | Methotrexate | Methoxyflurane | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness. | Moderate | 1 | [
[
[
663,
24,
1332
]
],
[
[
663,
25,
1512
],
[
1512,
24,
1332
]
],
[
[
663,
63,
589
],
[
589,
24,
1332
]
],
[
[
663,
24,
50
],
[
50,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Di... | Methotrexate may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Methotrexate may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Methotrexate may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Methoxyflurane
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may lead to a major life threatening interaction when taken with Methoxyflurane
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may lead to a major life threatening interaction when taken with Methoxyflurane
Methotrexate may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Methoxyflurane |
DB00427 | DB00662 | 1,233 | 717 | [
"DDInter1879",
"DDInter1873"
] | Triprolidine | Trimethobenzamide | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. | Moderate | 1 | [
[
[
1233,
24,
717
]
],
[
[
1233,
24,
1382
],
[
1382,
63,
717
]
],
[
[
1233,
24,
109
],
[
109,
24,
717
]
],
[
[
1233,
63,
695
],
[
695,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Triprolidine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Triprolidine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Trimethobenzamide
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Trimethobenzamide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Trimethobenzamide (Compound) |
DB06168 | DB11988 | 1,531 | 270 | [
"DDInter281",
"DDInter1321"
] | Canakinumab | Ocrelizumab | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Moderate | 1 | [
[
[
1531,
24,
270
]
],
[
[
1531,
23,
1193
],
[
1193,
23,
270
]
],
[
[
1531,
62,
1461
],
[
1461,
23,
270
]
],
[
[
1531,
24,
1060
],
[
1060,... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
... | Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab and Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Canakinumab may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Canakinumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab
Canakinumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ocrelizumab |
DB00619 | DB00679 | 1,419 | 684 | [
"DDInter909",
"DDInter1796"
] | Imatinib | Thioridazine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias. | Major | 2 | [
[
[
1419,
25,
684
]
],
[
[
1419,
24,
1237
],
[
1237,
40,
684
]
],
[
[
1419,
63,
216
],
[
216,
1,
684
]
],
[
[
1419,
24,
9
],
[
9,
1,... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomiprami... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Thioridazine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Thioridazine (Compound)
Imatinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Thioridazine (Compound)
Imatinib (Compound) binds DDR1 (Gene) and DDR1 (Gene) is upregulated by Thioridazine (Compound)
Imatinib (Compound) downregulates ATP6V0B (Gene) and ATP6V0B (Gene) is upregulated by Thioridazine (Compound)
Imatinib (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Thioridazine (Compound)
Imatinib (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Thioridazine (Compound)
Imatinib (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Thioridazine (Compound) |
DB00261 | DB06595 | 702 | 1,491 | [
"DDInter93",
"DDInter1214"
] | Anagrelide | Midostaurin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Major | 2 | [
[
[
702,
25,
1491
]
],
[
[
702,
23,
112
],
[
112,
23,
1491
]
],
[
[
702,
25,
888
],
[
888,
24,
1491
]
],
[
[
702,
24,
657
],
[
657,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Anagrelide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anagrelide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anagrelide may lead to a major life threatening interaction when taken with Vasopressin and Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Propofol and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Anagrelide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Midostaurin
Anagrelide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Midostaurin |
DB00802 | DB01362 | 1,322 | 497 | [
"DDInter43",
"DDInter960"
] | Alfentanil | Iohexol | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1322,
25,
497
]
],
[
[
1322,
21,
29750
],
[
29750,
60,
497
]
],
[
[
1322,
63,
999
],
[
999,
25,
497
]
],
[
[
1322,
40,
704
],
[
704,
... | [
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Alfentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Injection site pain"
],
[
"Injection site pain",
"{u} (Side Effect) is ca... | Alfentanil (Compound) causes Injection site pain (Side Effect) and Injection site pain (Side Effect) is caused by Iohexol (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol
Alfentanil (Compound) resembles Fentanyl (Compound) and Fentanyl may lead to a major life threatening interaction when taken with Iohexol
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Iohexol
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may lead to a major life threatening interaction when taken with Iohexol
Alfentanil may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Iohexol
Alfentanil may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Iohexol
Alfentanil may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may lead to a major life threatening interaction when taken with Iohexol
Alfentanil (Compound) causes Injection site pain (Side Effect) and Injection site pain (Side Effect) is caused by Iodixanol (Compound) and Iodixanol (Compound) resembles Iohexol (Compound) |
DB01267 | DB11057 | 519 | 720 | [
"DDInter1381",
"DDInter1223"
] | Paliperidone | Mineral oil | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced by solvent extraction, catalytic hydrotreating, or hydrocracking. Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds (PAC) can lead to skin cancer. Mineral oil is a common ingredient in baby lotions, cold creams, ointments and cosmetics to treat and prevent dry, rough, scaly, itchy skin and minor skin irritations. It is also used as a mild laxative for human or veterinary uses. | Moderate | 1 | [
[
[
519,
24,
720
]
],
[
[
519,
24,
927
],
[
927,
63,
720
]
],
[
[
519,
24,
1151
],
[
1151,
24,
720
]
],
[
[
519,
25,
1069
],
[
1069,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone (Compound) resembles Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil |
DB00364 | DB06292 | 417 | 549 | [
"DDInter1717",
"DDInter474"
] | Sucralfate | Dapagliflozin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021. | Moderate | 1 | [
[
[
417,
24,
549
]
],
[
[
417,
24,
1344
],
[
1344,
40,
549
]
],
[
[
417,
21,
30077
],
[
30077,
60,
549
]
],
[
[
417,
23,
1630
],
[
1630,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Sucralfate (Compound) causes Fluid overload (Side Effect) and Fluid overload (Side Effect) is caused by Dapagliflozin (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine and Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Dapagliflozin |
DB00104 | DB08882 | 966 | 1,281 | [
"DDInter1323",
"DDInter1070"
] | Octreotide | Linagliptin | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011. | Moderate | 1 | [
[
[
966,
24,
1281
]
],
[
[
966,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
966,
21,
28966
],
[
28966,
60,
1281
]
],
[
[
966,
24,
154
],
[
154,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Octreotide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Linagliptin (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Octreotide (Compound) resembles Pasireotide (Compound) and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Octreotide may lead to a major life threatening interaction when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Linagliptin
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound) |
DB00364 | DB00850 | 417 | 1,630 | [
"DDInter1717",
"DDInter1432"
] | Sucralfate | Perphenazine | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Minor | 0 | [
[
[
417,
23,
1630
]
],
[
[
417,
23,
508
],
[
508,
40,
1630
]
],
[
[
417,
21,
28643
],
[
28643,
60,
1630
]
],
[
[
417,
24,
115
],
[
115,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perphenazine"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promazine"
],
[
... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Promazine and Promazine (Compound) resembles Perphenazine (Compound)
Sucralfate (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Perphenazine (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Perphenazine
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Perphenazine
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Methdilazine and Methdilazine (Compound) resembles Perphenazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine |
DB00364 | DB12455 | 417 | 933 | [
"DDInter1717",
"DDInter1336"
] | Sucralfate | Omadacycline | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings. | Moderate | 1 | [
[
[
417,
24,
933
]
],
[
[
417,
24,
1384
],
[
1384,
24,
933
]
],
[
[
417,
24,
1384
],
[
1384,
24,
428
],
[
428,
63,
933
]
],
[
[
417,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate and Calcium citrate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Sucralfate (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Calcium chloride (Compound) and Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Omadacycline
Sucralfate (Compound) causes Fluid overload (Side Effect) and Fluid overload (Side Effect) is caused by Isotretinoin (Compound) and Isotretinoin may lead to a major life threatening interaction when taken with Omadacycline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium chloride and Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline |
DB00041 | DB01116 | 1,648 | 601 | [
"DDInter38",
"DDInter1872"
] | Aldesleukin | Trimethaphan | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Moderate | 1 | [
[
[
1648,
24,
601
]
],
[
[
1648,
24,
537
],
[
537,
1,
601
]
],
[
[
1648,
24,
1264
],
[
1264,
63,
601
]
],
[
[
1648,
24,
714
],
[
714,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethaphan"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Trimethaphan (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Aldesleukin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Trimethaphan (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Trimethaphan (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Trimethaphan (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Bepridil and Bepridil (Compound) resembles Trimethaphan (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Trimethaphan (Compound) |
DB08873 | DB11730 | 74 | 351 | [
"DDInter221",
"DDInter1588"
] | Boceprevir | Ribociclib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
74,
25,
351
]
],
[
[
74,
24,
466
],
[
466,
62,
351
]
],
[
[
74,
25,
283
],
[
283,
62,
351
]
],
[
[
74,
63,
310
],
[
310,
24,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Boceprevir may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Boceprevir may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Boceprevir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Boceprevir may lead to a major life threatening interaction when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Boceprevir may cause a minor interaction that can limit clinical effects when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib |
DB01211 | DB06717 | 609 | 875 | [
"DDInter393",
"DDInter778"
] | Clarithromycin | Fosaprepitant | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
609,
24,
875
]
],
[
[
609,
63,
723
],
[
723,
1,
875
]
],
[
[
609,
21,
29340
],
[
29340,
60,
875
]
],
[
[
609,
62,
222
],
[
222,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Clarithromycin (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Fosaprepitant (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Clarithromycin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Clarithromycin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant |
DB00619 | DB14761 | 1,419 | 242 | [
"DDInter909",
"DDInter1578"
] | Imatinib | Remdesivir | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020. | Moderate | 1 | [
[
[
1419,
24,
242
]
],
[
[
1419,
24,
1130
],
[
1130,
24,
242
]
],
[
[
1419,
63,
1512
],
[
1512,
24,
242
]
],
[
[
1419,
25,
1377
],
[
1377,... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Imatinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Imatinib may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir |
DB00581 | DB05294 | 355 | 1,069 | [
"DDInter1018",
"DDInter1917"
] | Lactulose | Vandetanib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
355,
24,
1069
]
],
[
[
355,
21,
28810
],
[
28810,
60,
1069
]
],
[
[
355,
24,
720
],
[
720,
63,
1069
]
],
[
[
355,
24,
688
],
[
688,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u}... | Lactulose (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Vandetanib (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Vandetanib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin may lead to a major life threatening interaction when taken with Vandetanib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dofetilide and Dofetilide may lead to a major life threatening interaction when taken with Vandetanib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) resembles Vandetanib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Vandetanib
Lactulose (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Erlotinib (Compound) and Erlotinib (Compound) resembles Vandetanib (Compound) |
DB00363 | DB01114 | 695 | 272 | [
"DDInter419",
"DDInter362"
] | Clozapine | Chlorpheniramine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
695,
24,
272
]
],
[
[
695,
24,
849
],
[
849,
63,
272
]
],
[
[
695,
24,
128
],
[
128,
24,
272
]
],
[
[
695,
40,
465
],
[
465,
1,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clozapine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Chlorpheniramine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Chlorpheniramine (Compound)
Clozapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Chlorpheniramine (Compound)
Clozapine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clozapine (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clozapine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine |
DB00404 | DB09481 | 523 | 460 | [
"DDInter54",
"DDInter1113"
] | Alprazolam | Magnesium carbonate | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
523,
23,
460
]
],
[
[
523,
24,
401
],
[
401,
23,
460
]
],
[
[
523,
40,
1382
],
[
1382,
23,
460
]
],
[
[
523,
1,
1565
],
[
1565,
... | [
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Alprazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Alprazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Alprazolam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Alprazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Alprazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate |
DB00087 | DB10315 | 599 | 1,137 | [
"DDInter41",
"DDInter1127"
] | Alemtuzumab | Measles virus vaccine live attenuated | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
599,
25,
1137
]
],
[
[
599,
24,
1042
],
[
1042,
24,
1137
]
],
[
[
599,
24,
119
],
[
119,
64,
1137
]
],
[
[
599,
63,
273
],
[
273,
... | [
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactid... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab and Tositumomab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Alemtuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Alemtuzumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab and Tositumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated |
DB01175 | DB01177 | 318 | 77 | [
"DDInter672",
"DDInter904"
] | Escitalopram | Idarubicin | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
318,
25,
77
]
],
[
[
318,
6,
12523
],
[
12523,
45,
77
]
],
[
[
318,
18,
5587
],
[
5587,
57,
77
]
],
[
[
318,
21,
28931
],
[
28931,
... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Ida... | Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound)
Escitalopram (Compound) downregulates SCAND1 (Gene) and SCAND1 (Gene) is downregulated by Idarubicin (Compound)
Escitalopram (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Escitalopram may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Escitalopram may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin |
DB03404 | DB11703 | 765 | 405 | [
"DDInter855",
"DDInter9"
] | Hemin | Acalabrutinib | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Moderate | 1 | [
[
[
765,
24,
405
]
],
[
[
765,
63,
383
],
[
383,
24,
405
]
],
[
[
765,
24,
1598
],
[
1598,
63,
405
]
],
[
[
765,
64,
984
],
[
984,
2... | [
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[... | Hemin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Hemin may lead to a major life threatening interaction when taken with Danazol and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Hemin may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may lead to a major life threatening interaction when taken with Acalabrutinib
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Acalabrutinib
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Acalabrutinib
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib |
DB01001 | DB08903 | 688 | 996 | [
"DDInter1632",
"DDInter170"
] | Salbutamol | Bedaquiline | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Moderate | 1 | [
[
[
688,
24,
996
]
],
[
[
688,
6,
8374
],
[
8374,
45,
996
]
],
[
[
688,
21,
29282
],
[
29282,
60,
996
]
],
[
[
688,
62,
112
],
[
112,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Salbutamol (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Bedaquiline
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Bedaquiline |
DB00475 | DB01377 | 1,119 | 1,283 | [
"DDInter355",
"DDInter1119"
] | Chlordiazepoxide | Magnesium oxide | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1119,
23,
1283
]
],
[
[
1119,
1,
905
],
[
905,
23,
1283
]
],
[
[
1119,
40,
1174
],
[
1174,
23,
1283
]
],
[
[
1119,
24,
104
],
[
104,
... | [
[
[
"Chlordiazepoxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Lorazepam"
],
[
"Lorazepam",
"{u} may ca... | Chlordiazepoxide (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Chlordiazepoxide (Compound) resembles Temazepam (Compound) and Temazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Chlordiazepoxide (Compound) resembles Lorazepam (Compound) and Lorazepam (Compound) resembles Temazepam (Compound) and Temazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Chlordiazepoxide (Compound) resembles Temazepam (Compound) and Temazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Chlordiazepoxide (Compound) resembles Halazepam (Compound) and Halazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide |
DB00193 | DB08875 | 534 | 1,618 | [
"DDInter1841",
"DDInter262"
] | Tramadol | Cabozantinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Major | 2 | [
[
[
534,
25,
1618
]
],
[
[
534,
23,
112
],
[
112,
23,
1618
]
],
[
[
534,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
534,
24,
480
],
[
480,
... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Tramadol may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Cabozantinib
Tramadol may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Cabozantinib
Tramadol may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Cabozantinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Cabozantinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may lead to a major life threatening interaction when taken with Cabozantinib |
DB09080 | DB12332 | 144 | 1,619 | [
"DDInter1331",
"DDInter1626"
] | Olodaterol | Rucaparib | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
144,
24,
1619
]
],
[
[
144,
63,
222
],
[
222,
23,
1619
]
],
[
[
144,
63,
87
],
[
87,
24,
1619
]
],
[
[
144,
24,
823
],
[
823,
24... | [
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib
Olodaterol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Rucaparib
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Rucaparib
Olodaterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Rucaparib |
DB04861 | DB09291 | 1,592 | 741 | [
"DDInter1271",
"DDInter1615"
] | Nebivolol | Rolapitant | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics. Nebivolol was granted FDA approval on 17 December 2007. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy. | Moderate | 1 | [
[
[
1592,
24,
741
]
],
[
[
1592,
63,
1264
],
[
1264,
24,
741
]
],
[
[
1592,
23,
578
],
[
578,
24,
741
]
],
[
[
1592,
24,
868
],
[
868,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Nebivolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Rolapitant
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Nebivolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Nebivolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant |
DB00710 | DB13749 | 1,199 | 1,473 | [
"DDInter897",
"DDInter1116"
] | Ibandronate | Magnesium gluconate | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA approval on 16 May 2003. | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids and laxatives) . Although magnesium is available in the form of sulphates, lactate, hydroxide, oxide and chloride, only magnesium gluconate is recommended for magnesium supplementation as it appears to be better absorbed and causes less diarrha . This drug has been studied in the prevention of pregnancy-induced hypertension, and has displayed promising results . In addition, it has been studied for its effects on premature uterine contractions . | Moderate | 1 | [
[
[
1199,
24,
1473
]
],
[
[
1199,
63,
544
],
[
544,
24,
1473
]
],
[
[
1199,
1,
1008
],
[
1008,
24,
1473
]
],
[
[
1199,
40,
1485
],
[
1485,... | [
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfat... | Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate (Compound) resembles Risedronic acid (Compound) and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate (Compound) resembles Risedronic acid (Compound) and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate |
DB00674 | DB05812 | 1,516 | 1,374 | [
"DDInter802",
"DDInter8"
] | Galantamine | Abiraterone | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Moderate | 1 | [
[
[
1516,
24,
1374
]
],
[
[
1516,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1516,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1516,
24,
112
],
[
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Galantamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Galantamine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Abiraterone
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Abiraterone |
DB00690 | DB12500 | 1,216 | 283 | [
"DDInter762",
"DDInter714"
] | Flurazepam | Fedratinib | A benzodiazepine derivative used mainly as a hypnotic. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1216,
24,
283
]
],
[
[
1216,
24,
351
],
[
351,
23,
283
]
],
[
[
1216,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1216,
1,
481
],
[
481,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Flurazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Flurazepam (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib |
DB00726 | DB01075 | 1,164 | 1,376 | [
"DDInter1876",
"DDInter569"
] | Trimipramine | Diphenhydramine | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Moderate | 1 | [
[
[
1164,
35,
1376
]
],
[
[
1164,
35,
649
],
[
649,
63,
1376
]
],
[
[
1164,
64,
11
],
[
11,
1,
1376
]
],
[
[
1164,
63,
128
],
[
128,
... | [
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate in... | Trimipramine (Compound) resembles Diphenhydramine (Compound) and
Trimipramine (Compound) resembles Clofedanol (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Trimipramine may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Diphenhydramine (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Trimipramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Trimipramine (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Diphenhydramine (Compound)
Trimipramine (Compound) resembles Dimetindene (Compound) and Dimetindene (Compound) resembles Diphenhydramine (Compound)
Trimipramine (Compound) resembles Promethazine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Diphenhydramine (Compound) |
DB00477 | DB04837 | 216 | 649 | [
"DDInter363",
"DDInter407"
] | Chlorpromazine | Clofedanol | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
216,
24,
649
]
],
[
[
216,
24,
1376
],
[
1376,
24,
649
]
],
[
[
216,
1,
293
],
[
293,
40,
649
]
],
[
[
216,
24,
832
],
[
832,
40... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlorpromazine (Compound) resembles Imipramine (Compound) and Imipramine (Compound) resembles Clofedanol (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Clofedanol (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlorpromazine (Compound) resembles Promethazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Chlorpromazine (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Clofedanol (Compound)
Chlorpromazine (Compound) resembles Alimemazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Clofedanol (Compound)
Chlorpromazine may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Clofedanol (Compound)
Chlorpromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol |
DB00222 | DB11943 | 245 | 255 | [
"DDInter825",
"DDInter495"
] | Glimepiride | Delafloxacin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. | Major | 2 | [
[
[
245,
25,
255
]
],
[
[
245,
24,
450
],
[
450,
23,
255
]
],
[
[
245,
24,
1283
],
[
1283,
24,
255
]
],
[
[
245,
24,
1619
],
[
1619,
... | [
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide may lead to a major life threatening interaction when taken with Delafloxacin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may lead to a major life threatening interaction when taken with Delafloxacin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may lead to a major life threatening interaction when taken with Delafloxacin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound) and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin |
DB00215 | DB12500 | 1,230 | 283 | [
"DDInter388",
"DDInter714"
] | Citalopram | Fedratinib | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1230,
25,
283
]
],
[
[
1230,
25,
351
],
[
351,
23,
283
]
],
[
[
1230,
23,
1419
],
[
1419,
24,
283
]
],
[
[
1230,
64,
600
],
[
600,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} m... | Citalopram may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Citalopram may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Citalopram may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Citalopram may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Citalopram (Compound) resembles Escitalopram (Compound) and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Citalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Citalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Citalopram may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib |
DB00218 | DB01278 | 1,176 | 1,021 | [
"DDInter1247",
"DDInter1506"
] | Moxifloxacin | Pramlintide | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1176,
24,
1021
]
],
[
[
1176,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
1176,
1,
1539
],
[
1539,
24,
1021
]
],
[
[
1176,
25,
891
],
[
891,... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
... | Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Moxifloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Moxifloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Moxifloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Moxifloxacin may lead to a major life threatening interaction when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Moxifloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Pramlintide
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide |
DB00712 | DB06603 | 1,274 | 39 | [
"DDInter763",
"DDInter1387"
] | Flurbiprofen | Panobinostat | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
1274,
37,
39
]
],
[
[
1274,
23,
479
],
[
479,
23,
39
]
],
[
[
1274,
63,
912
],
[
912,
24,
39
]
],
[
[
1274,
24,
1627
],
[
1627,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Flurbiprofen",
"{u} may cause a minor interaction that ca... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and
Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Flurbiprofen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Flurbiprofen may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Panobinostat |
DB00073 | DB00087 | 1,394 | 599 | [
"DDInter1608",
"DDInter41"
] | Rituximab | Alemtuzumab | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab). | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing.[L43397, L30335] | Moderate | 1 | [
[
[
1394,
24,
599
]
],
[
[
1394,
24,
597
],
[
597,
63,
599
]
],
[
[
1394,
63,
1184
],
[
1184,
24,
599
]
],
[
[
1394,
64,
581
],
[
581,
... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Rituximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Rituximab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Rituximab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Alemtuzumab
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Levamisole and Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Levamisole and Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Rituximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab |
DB00682 | DB00758 | 126 | 1,347 | [
"DDInter1951",
"DDInter413"
] | Warfarin | Clopidogrel | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997. | Major | 2 | [
[
[
126,
25,
1347
]
],
[
[
126,
63,
1018
],
[
1018,
25,
1347
]
],
[
[
126,
6,
3486
],
[
3486,
45,
1347
]
],
[
[
126,
23,
671
],
[
671,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine"... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Warfarin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Clopidogrel (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Fluvastatin and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Warfarin may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Clopidogrel
Warfarin (Compound) resembles Modafinil (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate and Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel
Warfarin may lead to a major life threatening interaction when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel |
DB01006 | DB01254 | 300 | 1,213 | [
"DDInter1040",
"DDInter484"
] | Letrozole | Dasatinib | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Moderate | 1 | [
[
[
300,
24,
1213
]
],
[
[
300,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
300,
18,
10496
],
[
10496,
57,
1213
]
],
[
[
300,
21,
28882
],
[
2888... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Letrozole (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Dasatinib (Compound)
Letrozole (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Letrozole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Letrozole may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir and Boceprevir may lead to a major life threatening interaction when taken with Dasatinib
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan may lead to a major life threatening interaction when taken with Dasatinib |
DB00358 | DB00365 | 1,010 | 839 | [
"DDInter1140",
"DDInter842"
] | Mefloquine | Grepafloxacin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Major | 2 | [
[
[
1010,
25,
839
]
],
[
[
1010,
23,
112
],
[
112,
62,
839
]
],
[
[
1010,
63,
1101
],
[
1101,
23,
839
]
],
[
[
1010,
24,
286
],
[
286,
... | [
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Grepafloxacin
Mefloquine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Grepafloxacin
Mefloquine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Grepafloxacin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Grepafloxacin
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin |
DB11110 | DB12141 | 603 | 971 | [
"DDInter1115",
"DDInter817"
] | Magnesium citrate | Gilteritinib | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
603,
24,
971
]
],
[
[
603,
63,
485
],
[
485,
24,
971
]
],
[
[
603,
24,
730
],
[
730,
63,
971
]
],
[
[
603,
24,
1297
],
[
1297,
2... | [
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine... | Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib |
DB00188 | DB09570 | 168 | 1,480 | [
"DDInter222",
"DDInter1002"
] | Bortezomib | Ixazomib | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Moderate | 1 | [
[
[
168,
24,
1480
]
],
[
[
168,
24,
987
],
[
987,
63,
1480
]
],
[
[
168,
63,
440
],
[
440,
24,
1480
]
],
[
[
168,
23,
1094
],
[
1094,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR s... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Bortezomib may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Ixazomib
Bortezomib may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Ixazomib
Bortezomib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixazomib
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib |
DB01222 | DB01319 | 617 | 34 | [
"DDInter246",
"DDInter777"
] | Budesonide | Fosamprenavir | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Major | 2 | [
[
[
617,
25,
34
]
],
[
[
617,
64,
1091
],
[
1091,
40,
34
]
],
[
[
617,
6,
8374
],
[
8374,
45,
34
]
],
[
[
617,
21,
28723
],
[
28723,
... | [
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u... | Budesonide may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Budesonide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Budesonide (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Fosamprenavir (Compound)
Budesonide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fosamprenavir
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Budesonide may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Budesonide (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Budesonide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir |
DB00959 | DB06372 | 1,486 | 259 | [
"DDInter1191",
"DDInter1594"
] | Methylprednisolone | Rilonacept | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Moderate | 1 | [
[
[
1486,
24,
259
]
],
[
[
1486,
23,
1114
],
[
1114,
62,
259
]
],
[
[
1486,
62,
1461
],
[
1461,
23,
259
]
],
[
[
1486,
24,
1619
],
[
1619,... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"... | Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Methylprednisolone may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel and Brexucabtagene autoleucel may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Methylprednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Methylprednisolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin and Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Alprazolam and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept |
DB00446 | DB00549 | 597 | 522 | [
"DDInter351",
"DDInter1955"
] | Chloramphenicol | Zafirlukast | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Moderate | 1 | [
[
[
597,
24,
522
]
],
[
[
597,
6,
8374
],
[
8374,
45,
522
]
],
[
[
597,
21,
28784
],
[
28784,
60,
522
]
],
[
[
597,
23,
479
],
[
479,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zafirlukast (Compound)
Chloramphenicol (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Zafirlukast (Compound)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Chloramphenicol may lead to a major life threatening interaction when taken with Guanfacine and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast |
DB00222 | DB01144 | 245 | 1,326 | [
"DDInter825",
"DDInter540"
] | Glimepiride | Diclofenamide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
245,
24,
1326
]
],
[
[
245,
24,
504
],
[
504,
1,
1326
]
],
[
[
245,
24,
359
],
[
359,
40,
1326
]
],
[
[
245,
6,
6017
],
[
6017,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Diclofenamide (Compound)
Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Diclofenamide (Compound)
Glimepiride (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Diclofenamide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may lead to a major life threatening interaction when taken with Diclofenamide |
DB00341 | DB00454 | 1,242 | 1,349 | [
"DDInter343",
"DDInter1150"
] | Cetirizine | Meperidine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Moderate | 1 | [
[
[
1242,
24,
1349
]
],
[
[
1242,
24,
1688
],
[
1688,
1,
1349
]
],
[
[
1242,
40,
11366
],
[
11366,
1,
1349
]
],
[
[
1242,
21,
28717
],
[
2... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Meperidine (Compound)
Cetirizine (Compound) resembles Anileridine (Compound) and Anileridine (Compound) resembles Meperidine (Compound)
Cetirizine (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Meperidine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Meperidine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Meperidine |
DB00472 | DB01309 | 758 | 1,254 | [
"DDInter758",
"DDInter933"
] | Fluoxetine | Insulin glulisine | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
758,
24,
1254
]
],
[
[
758,
24,
1033
],
[
1033,
63,
1254
]
],
[
[
758,
63,
1424
],
[
1424,
24,
1254
]
],
[
[
758,
24,
480
],
[
480,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine |
DB00745 | DB11730 | 307 | 351 | [
"DDInter1236",
"DDInter1588"
] | Modafinil | Ribociclib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
307,
24,
351
]
],
[
[
307,
24,
466
],
[
466,
62,
351
]
],
[
[
307,
25,
283
],
[
283,
62,
351
]
],
[
[
307,
23,
310
],
[
310,
24,... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Modafinil may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Modafinil may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Modafinil may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib |
DB01563 | DB06691 | 680 | 849 | [
"DDInter349",
"DDInter1155"
] | Chloral hydrate | Mepyramine | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
680,
24,
849
]
],
[
[
680,
63,
1594
],
[
1594,
24,
849
]
],
[
[
680,
24,
407
],
[
407,
63,
849
]
],
[
[
680,
64,
475
],
[
475,
2... | [
[
[
"Chloral hydrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Chloral hydrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]... | Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Chloral hydrate may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Chloral hydrate may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB00631 | DB04855 | 372 | 540 | [
"DDInter405",
"DDInter602"
] | Clofarabine | Dronedarone | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone. | Moderate | 1 | [
[
[
372,
24,
540
]
],
[
[
372,
24,
33
],
[
33,
40,
540
]
],
[
[
372,
21,
28883
],
[
28883,
60,
540
]
],
[
[
372,
24,
896
],
[
896,
2... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Clofarabine (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dronedarone (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Clofarabine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Clofarabine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Dronedarone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Dronedarone |
DB00970 | DB01206 | 0 | 37 | [
"DDInter466",
"DDInter1086"
] | Dactinomycin | Lomustine | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
0,
24,
37
]
],
[
[
0,
21,
28722
],
[
28722,
60,
37
]
],
[
[
0,
62,
1176
],
[
1176,
23,
37
]
],
[
[
0,
23,
255
],
[
255,
62,
... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Dactinomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused ... | Dactinomycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Dactinomycin may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Lomustine |
DB00582 | DB14568 | 1,622 | 982 | [
"DDInter1946",
"DDInter1000"
] | Voriconazole | Ivosidenib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Major | 2 | [
[
[
1622,
25,
982
]
],
[
[
1622,
23,
112
],
[
112,
23,
982
]
],
[
[
1622,
63,
168
],
[
168,
23,
982
]
],
[
[
1622,
64,
1101
],
[
1101,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Voriconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Voriconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Voriconazole may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Voriconazole may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Voriconazole may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Montelukast and Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Voriconazole may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib |
DB00289 | DB00604 | 847 | 1,425 | [
"DDInter132",
"DDInter385"
] | Atomoxetine | Cisapride | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
847,
25,
1425
]
],
[
[
847,
24,
883
],
[
883,
1,
1425
]
],
[
[
847,
6,
10215
],
[
10215,
45,
1425
]
],
[
[
847,
23,
112
],
[
112,
... | [
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib"... | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Cisapride (Compound)
Atomoxetine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Cisapride (Compound)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cisapride
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Atomoxetine (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Cisapride
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may lead to a major life threatening interaction when taken with Cisapride
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Cisapride
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Cisapride |
DB06824 | DB14491 | 29 | 428 | [
"DDInter1864",
"DDInter725"
] | Triethylenetetramine | Ferrous fumarate | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease, TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and tolerant to [penicillamine]. TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335] | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
29,
24,
428
]
],
[
[
29,
23,
1193
],
[
1193,
23,
428
]
],
[
[
29,
24,
286
],
[
286,
24,
428
]
],
[
[
29,
63,
1283
],
[
1283,
24,... | [
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zin... | Triethylenetetramine may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Triethylenetetramine may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate and Calcium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate |
DB00981 | DB08865 | 1,528 | 1,593 | [
"DDInter1462",
"DDInter448"
] | Physostigmine | Crizotinib | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
1528,
24,
1593
]
],
[
[
1528,
21,
28658
],
[
28658,
60,
1593
]
],
[
[
1528,
63,
479
],
[
479,
23,
1593
]
],
[
[
1528,
63,
461
],
[
461... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is ... | Physostigmine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Crizotinib (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Physostigmine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine may lead to a major life threatening interaction when taken with Crizotinib
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Crizotinib
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Crizotinib |
DB00624 | DB00687 | 1,561 | 870 | [
"DDInter1775",
"DDInter747"
] | Testosterone | Fludrocortisone | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Moderate | 1 | [
[
[
1561,
24,
870
]
],
[
[
1561,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1561,
40,
1222
],
[
1222,
40,
870
]
],
[
[
1561,
63,
251
],
[
251,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Testosterone (Compound) resembles Megestrol acetate (Compound) and Megestrol acetate (Compound) resembles Fludrocortisone (Compound)
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludrocortisone (Compound)
Testosterone (Compound) resembles Hydrocortamate (Compound) and Hydrocortamate (Compound) resembles Fludrocortisone (Compound)
Testosterone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Testosterone (Compound) binds AR (Gene) and AR (Gene) is bound by Fludrocortisone (Compound)
Testosterone (Compound) causes Amenorrhoea (Side Effect) and Amenorrhoea (Side Effect) is caused by Fludrocortisone (Compound)
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Testosterone (Compound) resembles Stanozolol (Compound) and Stanozolol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone |
DB00047 | DB00275 | 176 | 217 | [
"DDInter932",
"DDInter1330"
] | Insulin glargine | Olmesartan | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. By comparison, the angiotensin-converting enzyme inhibitor (ACEi) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibit the conversion of angiotensin I to angiotensin II through inhibition of the ACE enzyme. However, this does not prevent the formation of all angiotensin II within the body. The angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. Olmesartan is commonly used for the management of hypertension and Type 2 Diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors. ARBs such as olmesartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization.[A174124,A178153,A173869,A185324,A185327,A185333,A185342,A185345] Like other ARBs, olmesartan blockade of RAAS slows the progression of diabetic nephropathy due to its renoprotective effects.[A185906,A185909,A185912] Orally available olmesartan is produced as the prodrug olmesartan medoxomil which is rapidly converted _in vivo_ to the pharmacologically active olmesartan. It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882] | Moderate | 1 | [
[
[
176,
24,
217
]
],
[
[
176,
24,
911
],
[
911,
40,
217
]
],
[
[
176,
24,
1486
],
[
1486,
63,
217
]
],
[
[
176,
23,
1621
],
[
1621,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medo... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Olmesartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Olmesartan
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Candesartan (Compound) and Candesartan (Compound) resembles Olmesartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Losartan and Losartan (Compound) resembles Forasartan (Compound) and Forasartan (Compound) resembles Olmesartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Olmesartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Olmesartan (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Olmesartan (Compound) |
DB00295 | DB06209 | 475 | 256 | [
"DDInter1244",
"DDInter1508"
] | Morphine | Prasugrel | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. | Moderate | 1 | [
[
[
475,
24,
256
]
],
[
[
475,
6,
8374
],
[
8374,
45,
256
]
],
[
[
475,
21,
28681
],
[
28681,
60,
256
]
],
[
[
475,
24,
752
],
[
752,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Morphine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Morphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Morphine may lead to a major life threatening interaction when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Morphine (Compound) resembles Oxymorphone (Compound) and Morphine may lead to a major life threatening interaction when taken with Oxymorphone and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel |
DB08881 | DB08903 | 868 | 996 | [
"DDInter1925",
"DDInter170"
] | Vemurafenib | Bedaquiline | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Major | 2 | [
[
[
868,
25,
996
]
],
[
[
868,
63,
1376
],
[
1376,
1,
996
]
],
[
[
868,
6,
8374
],
[
8374,
45,
996
]
],
[
[
868,
21,
29106
],
[
29106,
... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Di... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Bedaquiline (Compound)
Vemurafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Vemurafenib (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Bedaquiline (Compound)
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Vemurafenib may lead to a major life threatening interaction when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline |
DB06754 | DB14357 | 707 | 944 | [
"DDInter471",
"DDInter347"
] | Danaparoid | Chamomile | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
707,
23,
944
]
],
[
[
707,
64,
256
],
[
256,
23,
944
]
],
[
[
707,
25,
498
],
[
498,
23,
944
]
],
[
[
707,
64,
256
],
[
256,
64,... | [
[
[
"Danaparoid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
... | Danaparoid may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may lead to a major life threatening interaction when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) resembles Prasugrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile |
DB00218 | DB06788 | 1,176 | 1,616 | [
"DDInter1247",
"DDInter864"
] | Moxifloxacin | Histrelin | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Major | 2 | [
[
[
1176,
25,
1616
]
],
[
[
1176,
23,
112
],
[
112,
23,
1616
]
],
[
[
1176,
25,
1342
],
[
1342,
24,
1616
]
],
[
[
1176,
24,
170
],
[
170,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Moxifloxacin may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Moxifloxacin may lead to a major life threatening interaction when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Moxifloxacin may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Moxifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Moxifloxacin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin |
DB00782 | DB08938 | 1,123 | 1,384 | [
"DDInter1535",
"DDInter1112"
] | Propantheline | Magaldrate | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1123,
24,
1384
]
],
[
[
1123,
24,
1178
],
[
1178,
23,
1384
]
],
[
[
1123,
63,
461
],
[
461,
23,
1384
]
],
[
[
1123,
62,
1252
],
[
1252... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Propantheline may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Propantheline may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Propantheline (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate |
DB00418 | DB00443 | 536 | 251 | [
"DDInter1650",
"DDInter195"
] | Secobarbital | Betamethasone | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Moderate | 1 | [
[
[
536,
24,
251
]
],
[
[
536,
24,
870
],
[
870,
1,
251
]
],
[
[
536,
24,
1486
],
[
1486,
40,
251
]
],
[
[
536,
21,
29081
],
[
29081,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (Compound)
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound) resembles Betamethasone (Compound)
Secobarbital (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Betamethasone (Compound)
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Secobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Secobarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Secobarbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone |
DB00694 | DB04948 | 51 | 1,084 | [
"DDInter485",
"DDInter1083"
] | Daunorubicin | Lofexidine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. | Moderate | 1 | [
[
[
51,
24,
1084
]
],
[
[
51,
23,
112
],
[
112,
23,
1084
]
],
[
[
51,
63,
618
],
[
618,
24,
1084
]
],
[
[
51,
24,
774
],
[
774,
63,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Daunorubicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Daunorubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Daunorubicin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lofexidine |
DB00530 | DB00736 | 1,195 | 660 | [
"DDInter667",
"DDInter676"
] | Erlotinib | Esomeprazole | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including , , and , for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including , , , , and . Esomeprazole is the s-isomer of , which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as , without any significant differences between the two compounds _in vitro_. Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists longer than 24 hours.[FDA Label] PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients such as iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life. Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. Esomeprazole doses should be slowly lowered, or tapered, before discontinuing to prevent this rebound effect. | Major | 2 | [
[
[
1195,
25,
660
]
],
[
[
1195,
64,
1215
],
[
1215,
40,
660
]
],
[
[
1195,
25,
379
],
[
379,
40,
660
]
],
[
[
1195,
64,
837
],
[
837,
... | [
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
]
],
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{... | Erlotinib may lead to a major life threatening interaction when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Erlotinib may lead to a major life threatening interaction when taken with Rabeprazole and Rabeprazole (Compound) resembles Esomeprazole (Compound)
Erlotinib may lead to a major life threatening interaction when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Esomeprazole (Compound)
Erlotinib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is palliated by Esomeprazole (Compound)
Erlotinib (Compound) causes Conjunctivitis (Side Effect) and Conjunctivitis (Side Effect) is caused by Esomeprazole (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Erlotinib (Compound) resembles Vandetanib (Compound) and Vandetanib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole |
DB01105 | DB01219 | 222 | 716 | [
"DDInter1665",
"DDInter473"
] | Sibutramine | Dantrolene | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
222,
24,
716
]
],
[
[
222,
6,
8374
],
[
8374,
45,
716
]
],
[
[
222,
21,
28698
],
[
28698,
60,
716
]
],
[
[
222,
24,
1609
],
[
1609,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
Sibutramine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dantrolene (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Sibutramine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Dantrolene |
DB00197 | DB06335 | 1,324 | 761 | [
"DDInter1881",
"DDInter1646"
] | Troglitazone | Saxagliptin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1324,
24,
761
]
],
[
[
1324,
24,
307
],
[
307,
23,
761
]
],
[
[
1324,
23,
1103
],
[
1103,
23,
761
]
],
[
[
1324,
24,
1491
],
[
1491,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Troglitazone may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Troglitazone may lead to a major life threatening interaction when taken with Lumateperone and Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Saxagliptin
Troglitazone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Saxagliptin |
DB00373 | DB00501 | 461 | 752 | [
"DDInter1809",
"DDInter380"
] | Timolol | Cimetidine | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Moderate | 1 | [
[
[
461,
24,
752
]
],
[
[
461,
6,
4973
],
[
4973,
45,
752
]
],
[
[
461,
21,
29551
],
[
29551,
60,
752
]
],
[
[
461,
23,
542
],
[
542,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Timolol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Timolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cimetidine (Compound)
Timolol (Compound) causes Block heart (Side Effect) and Block heart (Side Effect) is caused by Cimetidine (Compound)
Timolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Timolol may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Timolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Timolol may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Timolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine |
DB00731 | DB00865 | 1,144 | 939 | [
"DDInter1269",
"DDInter187"
] | Nateglinide | Benzphetamine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Moderate | 1 | [
[
[
1144,
24,
939
]
],
[
[
1144,
35,
1529
],
[
1529,
1,
939
]
],
[
[
1144,
1,
80
],
[
80,
40,
939
]
],
[
[
1144,
63,
508
],
[
508,
1... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Nateglinide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when ta... | Nateglinide (Compound) resembles Metamfetamine (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Benzphetamine (Compound)
Nateglinide (Compound) resembles Amphetamine (Compound) and Amphetamine (Compound) resembles Benzphetamine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Benzphetamine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Benzphetamine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) resembles Benzphetamine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine
Nateglinide (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine (Compound) resembles Benzphetamine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Benzphetamine (Compound)
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Benzphetamine (Compound) |
DB00373 | DB11363 | 461 | 1,276 | [
"DDInter1809",
"DDInter39"
] | Timolol | Alectinib | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance. | Moderate | 1 | [
[
[
461,
24,
1276
]
],
[
[
461,
1,
729
],
[
729,
24,
1276
]
],
[
[
461,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
461,
24,
1528
],
[
1528,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Timolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate inter... | Timolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol (Compound) resembles Penbutolol (Compound) and Penbutolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib |
DB00092 | DB00361 | 58 | 134 | [
"DDInter40",
"DDInter1939"
] | Alefacept | Vinorelbine | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC . It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting . A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug . | Moderate | 1 | [
[
[
58,
24,
134
]
],
[
[
58,
24,
147
],
[
147,
63,
134
]
],
[
[
58,
24,
1101
],
[
1101,
24,
134
]
],
[
[
58,
63,
599
],
[
599,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Vinorelbine
Alefacept may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Vinorelbine
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Vinorelbine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Vinorelbine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound) and Vincristine (Compound) resembles Vinorelbine (Compound) |
DB11952 | DB12130 | 800 | 1,017 | [
"DDInter612",
"DDInter1094"
] | Duvelisib | Lorlatinib | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
800,
24,
1017
]
],
[
[
800,
63,
608
],
[
608,
23,
1017
]
],
[
[
800,
63,
175
],
[
175,
24,
1017
]
],
[
[
800,
64,
976
],
[
976,
... | [
[
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Duvelisib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Duvelisib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Duvelisib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib |
DB00775 | DB06081 | 1,226 | 1,046 | [
"DDInter1818",
"DDInter286"
] | Tirofiban | Caplacizumab | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression. | Major | 2 | [
[
[
1226,
25,
1046
]
],
[
[
1226,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
1226,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
1226,
24,
1427
],
[
14... | [
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Tirofiban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Tirofiban may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Caplacizumab
Tirofiban may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Caplacizumab
Tirofiban may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Caplacizumab
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Caplacizumab
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Caplacizumab |
DB00598 | DB06705 | 1,523 | 1,106 | [
"DDInter1013",
"DDInter795"
] | Labetalol | Gadofosveset trisodium | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels. | Moderate | 1 | [
[
[
1523,
24,
1106
]
],
[
[
1523,
63,
457
],
[
457,
40,
1106
]
],
[
[
1523,
24,
796
],
[
796,
40,
1106
]
],
[
[
1523,
21,
28684
],
[
28684... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadofosveset trisodium (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid and Gadoxetic acid (Compound) resembles Gadofosveset trisodium (Compound)
Labetalol (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Gadofosveset trisodium (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid and Iopanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadoxetic acid (Compound) and Gadoxetic acid (Compound) resembles Gadofosveset trisodium (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid and Gadoxetic acid (Compound) resembles Gadodiamide (Compound) and Gadodiamide (Compound) resembles Gadofosveset trisodium (Compound)
Labetalol (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Gadoxetic acid (Compound) and Gadoxetic acid (Compound) resembles Gadofosveset trisodium (Compound)
Labetalol (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid and Iopanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium |
DB08912 | DB11691 | 1,040 | 1,499 | [
"DDInter462",
"DDInter1258"
] | Dabrafenib | Naldemedine | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Moderate | 1 | [
[
[
1040,
24,
1499
]
],
[
[
1040,
63,
307
],
[
307,
23,
1499
]
],
[
[
1040,
63,
932
],
[
932,
24,
1499
]
],
[
[
1040,
24,
960
],
[
960,
... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline and Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Dabrafenib may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Dabrafenib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Dabrafenib may lead to a major life threatening interaction when taken with Lonafarnib and Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Naldemedine |
DB00252 | DB08875 | 362 | 1,618 | [
"DDInter1460",
"DDInter262"
] | Phenytoin | Cabozantinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Major | 2 | [
[
[
362,
25,
1618
]
],
[
[
362,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
362,
24,
112
],
[
112,
23,
1618
]
],
[
[
362,
24,
723
],
[
723,
... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Phenytoin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Phenytoin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Phenytoin (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Phenytoin may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib |
DB08916 | DB13879 | 26 | 1,043 | [
"DDInter32",
"DDInter824"
] | Afatinib | Glecaprevir | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim. | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic barrier against resistance mutations of the virus. In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA Label]. The combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir resistance [FDA Label]. Glecaprevir is available as an oral combination therapy with under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis . Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both . Hepatitis C viral infection often leads to decreased liver function and subsequent liver failure, causing a significantly negative impact on the patients' quality of life. The ultimate goal of the combination treatment is to achieve sustained virologic response (SVR) and cure the patients from the infection. In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [FDA Label]. | Moderate | 1 | [
[
[
26,
24,
1043
]
],
[
[
26,
24,
466
],
[
466,
24,
1043
]
],
[
[
26,
63,
868
],
[
868,
24,
1043
]
],
[
[
26,
24,
1456
],
[
1456,
25... | [
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir |
DB00295 | DB11642 | 475 | 938 | [
"DDInter1244",
"DDInter1480"
] | Morphine | Pitolisant | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
475,
24,
938
]
],
[
[
475,
24,
1133
],
[
1133,
24,
938
]
],
[
[
475,
63,
701
],
[
701,
24,
938
]
],
[
[
475,
23,
1425
],
[
1425,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Morphine may cause a minor interaction that can limit clinical effects when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Pitolisant
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Terbinafine and Terbinafine may lead to a major life threatening interaction when taken with Pitolisant
Morphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Pitolisant
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Pitolisant
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant |
DB00384 | DB00959 | 1,275 | 1,486 | [
"DDInter1859",
"DDInter1191"
] | Triamterene | Methylprednisolone | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
1275,
24,
1486
]
],
[
[
1275,
24,
175
],
[
175,
40,
1486
]
],
[
[
1275,
24,
167
],
[
167,
1,
1486
]
],
[
[
1275,
21,
28714
],
[
28714,... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Triamterene (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Methylprednisolone (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Methylprednisolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Halobetasol Propionate (Compound) and Halobetasol Propionate (Compound) resembles Methylprednisolone (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Hydrocortamate (Compound) and Hydrocortamate (Compound) resembles Methylprednisolone (Compound) |
DB00477 | DB00902 | 216 | 104 | [
"DDInter363",
"DDInter1168"
] | Chlorpromazine | Methdilazine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
216,
35,
104
]
],
[
[
216,
40,
11224
],
[
11224,
1,
104
]
],
[
[
216,
1,
11237
],
[
11237,
1,
104
]
],
[
[
216,
63,
13
],
[
13,
... | [
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioproperazine"
... | Chlorpromazine (Compound) resembles Methdilazine (Compound) and
Chlorpromazine (Compound) resembles Thioproperazine (Compound) and Thioproperazine (Compound) resembles Methdilazine (Compound)
Chlorpromazine (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Methdilazine (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Chlorpromazine (Compound) resembles Isothipendyl (Compound) and Isothipendyl (Compound) resembles Methdilazine (Compound)
Chlorpromazine (Compound) resembles Alimemazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound)
Chlorpromazine (Compound) resembles Promethazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Chlorpromazine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Methdilazine (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Methdilazine |
DB06403 | DB08820 | 1,204 | 1,478 | [
"DDInter62",
"DDInter997"
] | Ambrisentan | Ivacaftor | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms. | Moderate | 1 | [
[
[
1204,
24,
1478
]
],
[
[
1204,
24,
1040
],
[
1040,
63,
1478
]
],
[
[
1204,
63,
482
],
[
482,
24,
1478
]
],
[
[
1204,
24,
1491
],
[
1491... | [
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
... | Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ivacaftor
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Ivacaftor
Ambrisentan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ivacaftor
Ambrisentan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ivacaftor |
DB01166 | DB09065 | 477 | 760 | [
"DDInter379",
"DDInter424"
] | Cilostazol | Cobicistat | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Major | 2 | [
[
[
477,
25,
760
]
],
[
[
477,
63,
479
],
[
479,
23,
760
]
],
[
[
477,
24,
1374
],
[
1374,
23,
760
]
],
[
[
477,
25,
555
],
[
555,
2... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cilostazol may lead to a major life threatening interaction when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Cilostazol may lead to a major life threatening interaction when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Cilostazol may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Cilostazol (Compound) resembles Aripiprazole (Compound) and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Cilostazol may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat |
DB00087 | DB13007 | 599 | 1,060 | [
"DDInter41",
"DDInter642"
] | Alemtuzumab | Enfortumab vedotin | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Moderate | 1 | [
[
[
599,
24,
1060
]
],
[
[
599,
24,
270
],
[
270,
24,
1060
]
],
[
[
599,
63,
268
],
[
268,
24,
1060
]
],
[
[
599,
25,
1011
],
[
1011,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Alemtuzumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Enfortumab vedotin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Enfortumab vedotin
Alemtuzumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Enfortumab vedotin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Enfortumab vedotin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin |
DB01319 | DB06697 | 34 | 436 | [
"DDInter777",
"DDInter121"
] | Fosamprenavir | Artemether | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. | Major | 2 | [
[
[
34,
25,
436
]
],
[
[
34,
6,
8374
],
[
8374,
45,
436
]
],
[
[
34,
63,
353
],
[
353,
24,
436
]
],
[
[
34,
25,
283
],
[
283,
63,
... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Artemether"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"A... | Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Artemether (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Fosamprenavir may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Fosamprenavir may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Fosamprenavir (Compound) resembles Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Artemether
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Artemether
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Artemether
Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound) and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Artemether |
DB00609 | DB09122 | 595 | 1,613 | [
"DDInter694",
"DDInter1409"
] | Ethionamide | Peginterferon beta-1a | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
595,
24,
1613
]
],
[
[
595,
63,
168
],
[
168,
24,
1613
]
],
[
[
595,
24,
267
],
[
267,
24,
1613
]
],
[
[
595,
24,
1480
],
[
1480,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
... | Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethionamide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethionamide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethionamide (Compound) upregulates ZNF586 (Gene) and ZNF586 (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a |
DB00026 | DB01115 | 1,184 | 336 | [
"DDInter94",
"DDInter1291"
] | Anakinra | Nifedipine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Moderate | 1 | [
[
[
1184,
24,
336
]
],
[
[
1184,
24,
1428
],
[
1428,
1,
336
]
],
[
[
1184,
24,
1081
],
[
1081,
40,
336
]
],
[
[
1184,
24,
1031
],
[
1031,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Anakinra may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Anakinra may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Nifedipine |
DB00308 | DB01064 | 347 | 1,148 | [
"DDInter901",
"DDInter987"
] | Ibutilide | Isoprenaline | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Major | 2 | [
[
[
347,
25,
1148
]
],
[
[
347,
24,
480
],
[
480,
24,
1148
]
],
[
[
347,
21,
28722
],
[
28722,
60,
1148
]
],
[
[
347,
25,
1151
],
[
1151,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
]
],
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol... | Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Ibutilide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoprenaline (Compound)
Ibutilide may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Ibutilide may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Ibutilide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Ibutilide (Compound) resembles Dronedarone (Compound) and Dronedarone may lead to a major life threatening interaction when taken with Isoprenaline
Ibutilide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Isoprenaline
Ibutilide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Isoprenaline |
DB00457 | DB00687 | 1,205 | 870 | [
"DDInter1511",
"DDInter747"
] | Prazosin | Fludrocortisone | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624] | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Moderate | 1 | [
[
[
1205,
24,
870
]
],
[
[
1205,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1205,
63,
251
],
[
251,
40,
870
]
],
[
[
1205,
21,
28936
],
[
28936,... | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludrocortisone (Compound)
Prazosin (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Fludrocortisone (Compound)
Prazosin (Compound) resembles Terazosin (Compound) and Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Prazosin (Compound) resembles Doxazosin (Compound) and Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Fludrocortisone
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.